GCG and COVID-19: Researchers from Indonesia conducted a study that revealed a significant association between the pre-admission use of GLP-1 receptor agonists (GLP-1 RAs) and a reduction in mortality rates related to COVID-19 among patients with type 2 diabetes (T2DM).